Analyst Update: GoPro, Isis Pharmaceuticals, Yandex

Analysts adjusted their ratings on GoPro Inc (GPRO), ISIS Pharmaceuticals, Inc. (ISIS), and Yandex NV (YNDX)

Feb 4, 2015 at 11:39 AM
facebook twitter linkedin


Analysts are weighing in today on portable camera maker GoPro Inc (NASDAQ:GPRO), drugmaker ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS), and Russian search specialist Yandex NV (NASDAQ:YNDX). Here's a quick look at today's brokerage notes on GPRO, ISIS, and YNDX.

  • GPRO is down 5.2% today to trade at $51.73, after Citigroup slashed its target price to $59 from $94 while reiterating its "neutral" stance on the stock. What's more, GoPro Inc has shed about 18.2% year-to-date, recently hit by Apple Inc.'s (NASDAQ:AAPL) new action-camera patent, and will release earnings after the close tomorrow. Unsurprisingly, short sellers have flocked to the equity, with nearly 29% of GPRO's float sold short (about 14.3 million shares). Also, two-thirds of covering analysts rate the stock a "hold" or worse, and GPRO's consensus 12-month price target of $79.73 stands at a 54.1% premium to current trading levels.

  • Shares of ISIS have lost about 4.7% around midday to hit $61.67, following yesterday's announcement that the company's experimental type 2 diabetes drug doesn't perform as quickly as anticipated. In response, Piper Jaffray cut its price target to $68 from $81, and downgraded the stock to "neutral" from "overweight." Elsewhere, bearish sentiment in ISIS Pharmaceuticals, Inc.'s options pits is nearing a pessimistic peak. Specifically, ISIS' 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 1.76 sits just 9 percentage points from an annual high.

  • YNDX is up about 0.4% in intraday trading at $15.69, even after Renaissance Capital lowered its price target to $19.20 from $33.80 while underscoring a "buy" rating. On the charts, the stock has been a technical laggard, losing 57.2% year-over-year. However, sentiment in the options pits is bullish, with Yandex NV's 10-day ISE/CBOE/PHLX call/put volume ratio of 14.93 sitting higher than 95% of all other readings taken over the last year. The brokerage bunch is optimistic as well, with all eight covering analysts doling out a "buy" or better rating on the stock.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Stock Pick Report
 


 


 
Special Offers from Schaeffer's Trading Partners